Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES
Conclusion:
Male patients with metastatic RCC and hypogonadism receiving testosterone had less fatigue and better symptom control during targeted therapy.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hypothyroidism | Kidney Cancer | Low Testosterone | Renal Cell Carcinoma | Study | Urology & Nephrology